Biotech News
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
investors.artivion.com2026-05-06 14:57 EST
ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent